Entera Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>EB</div>
In spite of fairly weak basic indicators, Entera Bio showed solid returns over the last few months and may actually be approaching a breakup point. We currently estimate Entera Bio as overvalued. The real value is approaching 5.29 per share.
Published over a month ago
View all stories for Entera Bio | View All Stories
Does Entera Bio (NASDAQ:ENTX) have strong basic indicators based on the current rise?
We provide trade advice to complement the prevailing expert consensus on Entera Bio. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.

Are Entera Bio Earnings Expected to grow?

The future earnings power of Entera Bio involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Entera Bio factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Entera Bio stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Entera expected earnings.

How Entera utilizes its cash?

To perform a cash flow analysis of Entera Bio, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Entera Bio is receiving and how much cash it distributes out in a given period. The Entera Bio cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Entera Bio Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Entera Bio reported Net Cash Flow from Operations of (10.42 Million) in 2020

Entera Bio Gross Profit

Entera Bio Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Entera Bio previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Entera Bio Gross Profit growth over the last 10 years.
Please check Gross Profit in more details.

Detailed Perspective On Entera Bio

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Entera Bio is not uncomon. Institutional investors typically avoid acquiring a high percentage of Entera Bio stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Entera is distributed among investors.

Ownership Allocation

Entera Bio retains a total of 21.06 Million outstanding shares. Entera Bio retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Retail Investors
Retail Investors48.43
 2010 2019 2020 2021 (projected)
Revenues USD500 K236 K212.4 K266.74 K
Revenues500 K236 K212.4 K266.74 K

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Entera Bio has an asset utilization ratio of 2.6 percent. This suggests that the company is making $0.026 for each dollar of assets. An increasing asset utilization means that Entera Bio is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
16.1 M
Current Assets16.11 Million90.3
Assets Non Current1.17 Million6.58

Are Entera Bio technical ratios showing a come-back?

Current semi deviation is at 3.82. Entera Bio is displaying above-average volatility over the selected time horizon. Investors should scrutinize Entera Bio independently to ensure intended market timing strategies are aligned with expectations about Entera Bio volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Entera Bio's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Entera Bio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Entera Bio

While many of the other players within the biotechnology industry are still a little expensive, even after the recent corrections, Entera Bio may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor short any shares of Entera Bio at this time. The Entera Bio risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Entera Bio.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Entera Bio. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com